90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer.
Ethiodol (or lipiodol) is selectively retained in hepatocellular carcinoma and is used as a vehicle to deliver radioactive agents following intraarterial hepatic infusion. We prepared the lipophilic complex 90Y-oxine with a radiolabeling efficiency of 97.6+/-1.1%. After extraction into ethiodol, a stability test in serum at 37 degrees C showed that 87.8% of the 90Y remained ethiodol-bound for 7 days. Bremsstrahlung imaging of a rabbit for 48 h confirmed that the homogeneous mixture of radiolabeled 90Y-oxine and ethiodol stayed in the targeted liver lobe. This radiopharmaceutical is thus a potential candidate for the treatment of non-resectable liver cancer.
Department of Radiation Oncology, 9500 Euclid Avenue T28 Cleveland, OH 44195, USA.
Junfeng
J
Yu
Urs O
UO
Häfeli
Mark
M
Sands
Yonghua
Y
Dong
D000792:Angiography; D000818:Animals; D002855:Chromatography, Thin Layer; D004355:Drug Stability; D004998:Ethiodized Oil / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D006499:Hepatic Artery; D007205:Indium Radioisotopes / Q000737:chemistry; D007269:Injections, Intra-Arterial; D007553:Isotope Labeling / Q000379:methods; D008099:Liver / Q000000981:diagnostic imaging; D008114:Liver Neoplasms, Experimental / Q000532:radiotherapy*; D009928:Organ Specificity; D015125:Oxyquinoline / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D011817:Rabbits; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D015125:Oxyquinoline; D004998:Ethiodized Oil